TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30420883
Drug: 3.0 g IVMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g IVMP (1.0 g/day for 3 consecutive days) in DON (B1)
Study: 30420883
Drug: IVMP in
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP in every week schedule (cumulative dose 4.5 g) in GO (A3)
Study: 30421265
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment for uncomplicated appendicitis
Study: 30423055
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and Sequential Organ Failure Assessment Scores
Study: 30423165
Drug: Non-recommended rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-recommended rivaroxaban doses
Study: 30423165
Drug: Recommended rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recommended rivaroxaban doses
Study: 30425161
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for left-sided stroke
Study: 30425161
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for right-sided stroke
Study: 30425843
Drug: S-1 (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80-120 mg/day on days 1-28 every 42 days, four courses)
Study: 30425843
Drug: UFT/LV (UFT:
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses)
Study: 30426067
Drug: Long-chain n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain n-3 polyunsaturated fatty acids (1.5 g docosahexaenoic acid + eicosapentaenoic acid daily) and cocoa flavan-3-ols (500 mg n-3 FLAV daily)
Study: 30427584
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg b.i.d.
Study: 30427594
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Study: 30427836
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) administered via gastroscope to the descending part of the duodenum.
Study: 30428832
Drug: Clinical, neuropsychological,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical, neuropsychological, neuroimaging, and biological markers assessment
Study: 30428931
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell infusion
Study: 30429112
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity treatment with social support
Study: 30431498
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of BuChE activity by 100 U/L
Study: 30431498
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of AChE activity by 1 U/g of hemoglobin
Study: 30431500
Drug: Intra-operative colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative colloid administration
Study: 30442260
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion (VE) of 10 ml/kg
Study: 30442502
Drug: GSK2857916 (3.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2857916 (3.40 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 2)
Study: 30442502
Drug: GSK2857916 (0.03-4.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2857916 (0.03-4.60 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 1)
Study: 30443549
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied sensors for assessing the quality of 18F-FDG injections
Study: 30444283
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 4 weeks
Study: 30444686
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of chemotherapy
Study: 30444686
Drug: Eight cycles
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of chemotherapy
Study: 30444686
Drug: Pre-emptive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive chemotherapy for infants younger than 2 months with hepatomegaly
Study: 30446007
Drug: AZD9150 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 at 2 mg/kg
Study: 30446007
Drug: AZD9150 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 at 3 mg/kg
Study: 30446007
Drug: AZD9150 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 (both doses)
Study: 30446575
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to the 2015 ACR guideline
Study: 30446741
Drug: Low-dose anti-thymocyte
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose anti-thymocyte globulin (ATG) 5 mg/kg and low-dose posttransplant cyclophosphamide (PTCy) 50 mg/kg
Study: 30446785
Drug: BEZ235 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 1000 mg qd
Study: 30446785
Drug: BEZ235 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 1200 mg qd
Study: 30446785
Drug: BEZ235 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 1400 mg qd
Study: 30446785
Drug: BEZ235 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (both dosing schedules)
Study: 30447969
Drug: Conventional MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional MRI - abnormal signal in the posterior limb of internal capsule (PLIC)
Study: 30448343
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with FLOT in combination with surgical resection of the primary tumour and metastases
Study: 30449033
Drug: Endoscopic ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic ultrasound-guided injection of cyanoacrylate (CYA) and a less-expensive coil
Study: 30450591
Drug: Aurora B
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL LIQUID [AURORA BODY WASH CRISP WATERS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurora B kinase inhibitor BI 811283 in combination with cytarabine
Study: 30451655
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg once weekly for 24 weeks
Study: 30452500
Drug: ROP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROP treatment at 32 weeks' postmenstrual age
Study: 30452500
Drug: ROP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROP treatment at 33 weeks' postmenstrual age
Study: 30452666
Drug: VSV-EBOV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-EBOV vaccine (single-dose regimen)
Study: 30455171
Drug: Tablet-based app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based app for consent process
Study: 30456327
Drug: Daily Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily Isoniazid with peer counseling
Study: 30460518
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg bid (octogenarians)
Study: 30460518
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg bid (octogenarians with appropriately reduced dose)
Study: 30460684
Drug: Ixazomib 4
Normalized name: ixazomib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 4 mg and cyclophosphamide 300 mg/m² with low-dose dexamethasone
Study: 30461442
Drug: Nonmedical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmedical prescription stimulants (NPS) (days of NPS use)
Study: 30461441
Drug: Participants' perceptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants' perceptions about drug use behaviors among US adults
Study: 30462243
Drug: Diuretic-induced hyponatremia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-induced hyponatremia
Study: 30462688
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) patients
Study: 30466205
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) administered in the morning for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Study: 30466205
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) administered at mid-day for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Study: 30466410
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice/day)
Study: 30467013
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) therapy initiated, monitored for biliary concentrations during the first 7 days.
Study: 30467135
Drug: Fesoterodine, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine, administered over a treatment phase of 12 weeks (three cycles of 4 weeks each).
Study: 30467135
Drug: Standardised questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised questionnaires (AD symptoms and quality of life) and bladder and bowel diaries at the end of each treatment cycle.
Study: 30467809
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL methoxyflurane (self-administered via inhalation under supervision)
Study: 30467809
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC) including IV morphine for severe pain (NRS ≥ 7); IV paracetamol or ketoprofen for moderate pain (NRS 4-6)
Study: 30467809
Drug: Healthcare professional-rated
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-rated practicality of study treatment at 30 min after randomisation using a 5-point Likert scale
Study: 30468243
Drug: PI3K-targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3K-targeted drugs
Study: 30470569
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral drugs for chronic hepatitis C
Study: 30471345
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ICG
Study: 30471345
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ICG
Study: 30471345
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg ICG
Study: 30471345
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg ICG
Study: 30471345
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg ICG
Study: 30471555
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination (NC) containing red yeast rice and berberine
Study: 30471652
Drug: Ixazomib-cyclophosphamide-dexamethasone (ICd)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib-cyclophosphamide-dexamethasone (ICd) followed by ixazomib maintenance; 4.0 mg of ixazomib, 300 mg (Arm A) or 400 mg (Arm B)
Study: 30472553
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (cholecalciferol) 100,000 IU bolus dose followed by 20,000 IU per week
Study: 30472651
Drug: ld-IL2 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ld-IL2 (1 million IU/day for 5 days, followed by fortnightly injections for 6 months)
Study: 30472660
Drug: Continuous EEG
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous EEG monitoring with antiepileptic drugs (AEDs)
Study: 30472660
Drug: Continuous EEG
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous EEG monitoring without antiepileptic drugs (AEDs)
Study: 30473706
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin or oxaliplatin
Study: 30475950
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Study: 30476179
Drug: 17β-estradiol transdermal
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17β-estradiol transdermal patch (PATCH)
Study: 30476968
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m2) plus irinotecan (180 mg/m2) biweekly
Study: 30477436
Drug: Cognitive function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive function assessed by the Montreal Cognitive Assessment, Trail making A and B, ten-word immediate and delayed recall test, Controlled Oral Word Association, Global Deterioration Scale, Ascertain Dementia 8 item informant questionnaire.
Study: 30477455
Drug: PBI-4050 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBI-4050 at a total daily oral dose of 800 mg for an initial 24 weeks with continuation for an additional 36 or 48 weeks
Study: 30477513
Drug: Preparation from
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation from scratch
Study: 30477513
Drug: Food preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food preparation behaviors
Study: 30477544
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg IM ketamine
Study: 30477544
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg IM midazolam and 5 mg IM haloperidol
Study: 30478168
Drug: Intravenous colistimethate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous colistimethate sodium (CMS) with a loading dose of 9 million international units (MU) followed by a maintenance dose of 3 MU every 8 hours.
Study: 30478190
Drug: Vorolanib (X-82)
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib (X-82) 400 mg once daily (q.d.)
Study: 30478190
Drug: Vorolanib (X-82)
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib (X-82) 20-800 mg (various dosing regimens)
Study: 30480082
Drug: Resveratrol, glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol, glucose, and malate (RGM) - 15 mL per dose (5 g dextrose, 5 g malate, 5 mg resveratrol) twice a day for 1 year
Study: 30480082
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - matching placebo ingested with an 8 oz glass of commercial unsweetened grape juice twice a day for 1 year
Study: 30480323
Drug: Tocilizumab administered
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab administered by intravenous infusion (dosage regimen not specified)
Study: 30480323
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or intravenous glucocorticoid therapy
Study: 30480489
Drug: Reduced Dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Dose CT (RD)
Study: 30480489
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose CT (SD)
Study: 30485854
Drug: Nalmefene 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 18 mg taken as needed with psychosocial interventions
Study: 30486767
Drug: Total cell-free
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cell-free DNA levels above the median (9800 alleles/mL)
Study: 30486767
Drug: Total cell-free
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cell-free DNA levels below the median (9800 alleles/mL)
Study: 30487142
Drug: Concurrent measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent measurement of CRP
Study: 30487998
Drug: GP2015 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2015 (50 mg subcutaneously, once weekly for 24 weeks)
Study: 30487998
Drug: ETN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN (50 mg subcutaneously, once weekly for 24 weeks)
Study: 30488179
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (5 g/m2) individualized dosing using a fixed algorithm with 0-2 rate adjustments based on methotrexate levels during infusion
Study: 30488420
Drug: Immunoglobulin G-degrading
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS)
Study: 30497397
Drug: Triage system
Normalized name: Triage First Aid Station KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triage system (Rapid Emergency Triage and Treatment System - RETTS)
Study: 30497431
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with 10 Gy directed to the involved mediastinum/hilar stations and/or positive surgical margins, followed by adjuvant systemic therapy.
Study: 30497431
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with 30 Gy to the primary tumor for the unresectable patient.
Study: 30498390
Drug: SBI 5
Normalized name: Somatostatin Analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBI 5 g BID for 3 weeks
Study: 30498564
Drug: Pioglitazone 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 0.25 mg/kg once daily
Study: 30498564
Drug: Pioglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 0.5 mg/kg once daily
Study: 30498564
Drug: Pioglitazone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 0.75 mg/kg once daily
Study: 30499605
Drug: Dabigatran (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (standard dose)
Study: 30499605
Drug: Dabigatran (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (reduced dose)
Study: 30499605
Drug: Rivaroxaban (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (standard dose)
Study: 30499605
Drug: Rivaroxaban (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (reduced dose)
Study: 30499734
Drug: 10% intravenous
Normalized name: glucose 10% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% intravenous immunoglobulin (IVIG; Flebogamma) administered at 1 g/kg over two consecutive days
Study: 30501550
Drug: Hydroxyurea (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (15 to 20 mg/kg/day for 6 months, followed by dose escalation)
Study: 30501869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyper-CVAD and ponatinib (45 mg per day for the first 14 days of cycle 1, then reduced to 30 mg per day at cycle 2, and further to 15 mg once a complete molecular response was achieved)
Study: 30501869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyper-CVAD and ponatinib (maintenance with ponatinib daily at 30 mg or 15 mg, vincristine 2 mg intravenously on day 1, and prednisone 200 mg orally on days 1-5 monthly for 2 years)
Study: 30501870
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (10 mg)
Study: 30501870
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (15 mg)
Study: 30501916
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake in normal weight children (859.0 ± 195.9 mg)
Study: 30506110
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (H IV) treatment
Study: 30506283
Drug: Personalized PRRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized PRRT (adjusted injected activity to deliver a prescribed absorbed dose to the kidney)
Study: 30506309
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home spirometry and accelerometry during the peri-diagnostic period
Study: 30506309
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home spirometry and accelerometry
Study: 30506533
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (2 cycles of CapeOX or 3 cycles of mFOLFOX6) followed by elective surgery
Study: 30506533
Drug: Elective surgery
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective surgery without neoadjuvant chemotherapy
Study: 30508189
Drug: bDMARD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bDMARD monotherapy
Study: 30508189
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy and bDMARDs
Study: 30508620
Drug: Inverse-planned, multibeam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse-planned, multibeam intensity modulated radiation therapy (IMRT)
Study: 30509296
Drug: Successful cfDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful cfDNA assay without heparin
Study: 30509296
Drug: Heparin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (in vitro experiments)
Study: 31118759
Drug: Pregabalin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin, dosage and duration not specified